3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
22
Carcinoma, Hepatocellular
14
Small Cell Lung Carcinoma
10
Triple Negative Breast Neoplasms
9
Neoplasms
7
Breast Neoplasms
6
Urinary Bladder Neoplasms
5
Colorectal Neoplasms
5
Ovarian Neoplasms
4
Lung Neoplasms
4
Carcinoma, Renal Cell
4
Carcinoma, Transitional Cell
3
Carcinoma
3
Uterine Cervical Neoplasms
2
Melanoma
2
Colonic Neoplasms
2
Venous Thrombosis
1
Urologic Neoplasms
1
Stomach Neoplasms
1
Squamous Non-Small Cell Lung Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Diseases
1
Rectal Neoplasms
1
Radiation Pneumonitis
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Neoplasms
1
Peritoneal Neoplasms
1
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
1
Non-Squamous Non-Small Cell Lung Cancer
1
Non-Small-Cell Lung
1
Interventions
enzalutamide
2
Prednisone
2
Abiraterone Acetate
2
tasquinimod
1
sabizabulin
1
niraparib
1
darolutamide
1
atezolizumab
1
abiraterone
1
Radiosurgery
1
Docetaxel
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Prostatic Neoplasms, Castration-Resistant
×
atezolizumab
×
Clear all
NCT03016312
2024-08-09
IMbassador250
Hoffmann-La Roche
Phase 3
Completed
759 enrolled
22 charts